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SIRT1 is a NAD+-dependent enzyme that affects
metabolism by deacetylating key transcriptional
regulators of energy expenditure. Here, we tested
whether deletion of PARP-2, an alternative NAD+-
consuming enzyme, impacts on NAD+ bioavailability
and SIRT1 activity. Our results indicate that PARP-2
deficiency increases SIRT1 activity in cultured
myotubes. However, this increase was not due to
changes in NAD+ levels, but to an increase in SIRT1
expression, as PARP-2 acts as a direct negative
regulator of the SIRT1 promoter. PARP-2 deletion
in mice increases SIRT1 levels, promotes energy
expenditure, and increases mitochondrial content.
Furthermore, PARP-2/ mice were protected
against diet-induced obesity. Despite being insulin
sensitized, PARP-2/ mice were glucose intolerant
due to a defective pancreatic function. Hence, while
inhibition of PARP activity promotes oxidative
metabolism through SIRT1 activation, the use of
PARP inhibitors for metabolic purposes will require
further understanding of the specific functions of
different PARP family members.
INTRODUCTION
SIRT1 has recently emerged as a promising target in the battle
against a number of metabolic disorders, including obesity and
type 2 diabetes (Banks et al., 2008; Pfluger et al., 2008; Yu and
Auwerx, 2010). The ability of NAD+ levels to control SIRT1
activity gave rise to the hypothesis that artificial modulation of
NAD+ levels could be used to regulate SIRT1 (Houtkooper
et al., 2010; Sauve, 2009). Indeed, most physiological situations
where NAD+ is increased correlate with higher SIRT1 activity450 Cell Metabolism 13, 450–460, April 6, 2011 ª2011 Elsevier Inc.(Canto´ et al., 2009; Houtkooper et al., 2010; Sauve, 2009).
One interesting possibility to artificially modulate NAD+ levels
relies on the inhibition of alternative NAD+ consumers, such
as the poly(ADP-ribose) polymerases (PARPs) (Houtkooper
et al., 2010). Confirming this hypothesis, a number of different
labs have shown that the activity of the PARP-1 enzyme,
a major cellular NAD+ consumer, and SIRT1 are interrelated
due to the competition for the same limiting intracellular
NAD+ pool (Kolthur-Seetharam et al., 2006; Pillai et al., 2005;
Rajamohan et al., 2009). It is, however, not known whether
other PARP family members have similar effects on SIRT1
activity and global metabolism.
The poly(ADP-ribose) polymerase-2 (PARP-2) is a 66.2 kDa
nuclear protein with PARP activity capable of binding to aberrant
DNA forms (Ame´ et al., 1999). DNA binding of PARP-2 results in
its activation, and PARP-2 subsequently catalyzes the formation
of poly(ADP-ribose) polymers (PAR) onto itself and to different
acceptor proteins (Ame´ et al., 1999; Haenni et al., 2008; Ye´la-
mos et al., 2008). PARP-2 has a catalytic domain (amino acids
202–593) structurally similar to PARP-1 (Oliver et al., 2004), the
founding member of the PARP family. However, while it is known
that PARP-1 activity critically influences NAD+ bioavailability
(Sims et al., 1981), the possible effects of a secondary PARP
activity, like PARP-2, on intracellular NAD+ levels and global
metabolism in cells or organs has not yet been fully determined.
Previous studies already provide evidence that PARP-2
is involved in metabolic homeostasis, as it regulates the peroxi-
some proliferator-activated receptor g (PPARg), therefore
influencing adipocyte differentiation (Bai et al., 2007). The poten-
tial relevance of PARP-2 for NAD+ homeostasis, which would
impact on SIRT1 activity and global metabolism, prompted us
hence to fully examine the metabolic phenotype of germline
PARP-2/ mice. We show here how the absence of PARP-2
activates SIRT1 and promotes mitochondrial biogenesis in
muscle. However, our data also reveal that the absence of
PARP-2 leads to pancreatic failure upon high-fat feeding, under-
scoring the possibility of developing drugs that selectively inhibit
specific PARP proteins for metabolic indications.
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Figure 1. PARP-2 Regulates Oxidative Metabolism by Acting as a Transcriptional Repressor of SIRT1
(A) PARP-2 protein and mRNA levels were analyzed in C2C12 myotubes carrying a stably transfected scramble or PARP-2 shRNA.
(B) NAD+ content was evaluated in C2C12 myotubes treated with PJ34 (24 hr, 1 mM) or carrying a stable transfection of a scramble or a PARP-2 shRNA.
H2O2 treatment was performed for 1 hr.
(C) Total protein extracts from C2C12 myotubes treated as in (B) were used to test total PARylation.
(D) Scramble or PARP-2 shRNA were stably transfected in C2C12 myotubes that were infected with FLAG-PGC-1a. After 48 hr, total protein extracts were
obtained and used for FLAG immunoprecipitation and to test the markers indicated.
(E) SIRT1 mRNA levels were analyzed in C2C12 myotubes carrying a stable transfection with either scramble or a PARP-2 siRNA.
(F) The activity of nested deletions of the SIRT1 promoter was measured after PARP-2 depletion in C2C12 cells.
(G) The presence of PARP-2 on the SIRT1 (1 through 91) promoter was assessed in C2C12 cells by ChIP assays, using MMP2 as negative control.
(H and I) O2 consumption (H) andmRNA levels of themarkers indicated (I) weremeasured in C2C12myotubes carrying a stable transfectionwith either a scramble
() or a PARP-2 (+) shRNA and infectedwith adenovirus encoding for either a scramble () or a SIRT1 (+) shRNA. Unless otherwise indicated, white bars represent
scramble shRNA-transfected myotubes and black bars represent PARP-2 shRNA-transfected myotubes. All results are expressed as mean ± SD. * indicates
statistical difference versus PARP-2+/+ mice at p < 0.05.
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PARP-2 Modulates SIRT1 ActivityRESULTS
PARP-2 Regulates Oxidative Metabolism by Repressing
SIRT1 Transcription
In order to examine the potential role of PARP-2 as a regulator
of SIRT1 activity, we generated C2C12 myocytes stably trans-
fected with either a scrambled or a PARP-2 shRNA. PARP-2
mRNA and protein content is reduced by 80% in myotubes
from cells carrying the PARP-2 shRNA (Figure 1A). We next
evaluated whether this deficiency in PARP-2 activity affects
NAD+ homeostasis. While inhibition of total PARP activity with
the inhibitor PJ34 leads to increased intracellular NAD+ content,
a reduction in PARP-2 by itself did not affect total (Figure 1B) orCmitochondrial (Figure S1A) NAD+ levels. Similarly, knocking
down PARP-2 did not prevent H2O2-induced NAD
+ depletion,
while global inhibition of PARP activity with PJ34 did (Fig-
ure 1B). To further sustain our observations, we analyzed the
impact of the PARP-2 knockdown on global PARP activity by
checking H2O2-induced protein PARylation. While PJ34
completely reversed H2O2-induced PARylation, the knockdown
of PARP-2 could not prevent protein hyperPARylation (Fig-
ure 1C). These results confirm that PARP-2 is a secondary
PARP activity in the cell, as previously demonstrated
(Ame´ et al., 1999; Shieh et al., 1998). Furthermore, it also
suggests that PARP-2 depletion has little impact on NAD+
homeostasis.ell Metabolism 13, 450–460, April 6, 2011 ª2011 Elsevier Inc. 451
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Figure 2. General Physiologic Characteris-
tics of PARP-2–/– Mice
(A and B) PARP-2+/+ and /male mice (n = 15/13)
were weighed weekly (A), and food consumption
was measured (B).
(C–E) PARP-2+/+ and /male mice on a chow diet
(n = 6/6, age of 3 months) were subjected to indi-
rect calorimetry, where locomotor activity (C), O2
consumption (D), and RER (E) were determined.
(F) Fed and fasted blood glucose levels. Values are
expressed as mean ± SEM unless otherwise
stated. * indicates statistical difference versus
PARP-2+/+ mice at p < 0.05.
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PARP-2 Modulates SIRT1 ActivityGiven the absence of an impact on NAD+ homeostasis, it
was surprising to observe that myotubes in which PARP-2
had been knocked down displayed higher SIRT1 activity, as
demonstrated by reduced PGC-1a acetylation (Figure 1D, top
panels). We could not find any direct interaction between
PARP-2 and SIRT1 (Figure S1B), indicating that changes in
SIRT1 activity are not likely to happen through direct posttrans-
lational modification by PARP-2. Rather, the increase in SIRT1
activity was linked to increased SIRT1 content (Figure 1D,
bottom panels). The increase in SIRT1 protein was concomitant
to an increase in SIRT1 mRNA levels (Figure 1E). To explore
why SIRT1 mRNA levels were increased by transcriptional
induction, we used a reporter construct in which serial dele-
tions of the mouse SIRT1 promoter region controlled luciferase
expression (Figure 1F). These studies demonstrated that
knocking down PARP-2 promoted a 2-fold increase in
SIRT1 transcription through the very proximal promoter region
(91 bp), an effect that was maintained for the whole upstream
regulatory region that was analyzed (Figure 1F). In chromatin
immunoprecipitation (ChIP) assays, PARP-2 was shown to
bind directly to the proximal SIRT1 promoter (region between
the transcription start site and 91 bp) in C2C12 myotubes
(Figure 1G). The direct binding of PARP-2 on the SIRT1
promoter was also observed in a nonmurine cell line, like
293HEK cells (Figure S1C), as this proximal 91 bp region is
extremely conserved along evolution (Figure S1D). All these
results suggest that PARP-2 acts as a direct negative regulator
of the SIRT1 promoter. Consequently, a reduction of PARP-2
levels induces SIRT1 transcription, leading to higher SIRT1
protein levels and activity. An expected consequence of this
increase in SIRT1 activity is that a reduction in PARP-2 content
should lead to higher mitochondrial gene expression, by the
activation of PGC-1a through deacetylation, and to increased452 Cell Metabolism 13, 450–460, April 6, 2011 ª2011 Elsevier Inc.O2 consumption. This hypothesis turned
out to be correct, as cellular O2 con-
sumption was increased in PARP-2
knockdown cells (Figure 1H), concomi-
tant to the increase in expression of
genes related to lipid and mitochondrial
metabolism, such as medium chain acyl
coenzyme A dehydrogenase (MCAD),
NADH dehydrogenase (Ubiquinone) 1
alpha subcomplex subunit 2 (Ndufa2),
and cytochrome C (Cyt) (Figure 1I).Furthermore, using adenoviruses encoding for a shRNA for
SIRT1, we demonstrated that the increase in SIRT1 activity
contributed in a major fashion to the oxidative phenotype of
PARP-2-deficient myotubes (Figures 1H and 1I).General Physiological Characterization
of the PARP-2–/– Mice
All the experiments above illustrate that reducing PARP-2
activity might be useful to increase SIRT1 activity and, conse-
quently, potentiate oxidative metabolism. In order to gain further
insight into this mechanism, we next examined the metabolic
profile of the PARP-2/ mice. PARP-2/ mice were smaller
and leaner then their PARP-2+/+ littermates (Figure 2A). The
fact that there was no difference in food intake between the
PARP-2/ and PARP-2+/+ mice (Figure 2B) and that sponta-
neous locomotor activity was lower in the PARP-2/ mice
(Figure 2C) suggested that the difference in weight gain was
due to altered energy expenditure (EE). Indirect calorimetry,
however, indicated only a slight tendency toward a higher O2
consumption in chow-fed PARP-2/ mice compared to wild-
type littermates under basal conditions (Figure 2D). Interestingly,
RQ values indicate that during the dark phase, PARP-2/ mice
use lipid substrates as energy source at proportionally higher
rates than the PARP-2+/+ littermates (Figure 2E). Strikingly,
PARP-2/ mice were mildly hyperglycemic in both fed and
fasted states (Figure 2F), linked to a tendency toward lower
blood insulin levels in both fed (2.52 ± 0.24 mg/l for PARP-2+/+
versus 1.77 ± 0.13 mg/l for PARP-2/ mice) and fasted (0.77 ±
0.07 mg/l for PARP-2+/+ versus 0.71 ± 0.11 mg/l for PARP-2/
mice) states. Overall, these results illustrate that PARP-2
deletion promotes an increase in the use of fat as main energy
source, associated with a leaner phenotype.
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Figure 3. PARP-2–/– Muscles Have Higher SIRT1 Activity, Mitochondrial Content, and Oxidative Profile
(A) PARylation and PARP-2 levels in gastrocnemius muscle were determined by western blot. PARP-2 levels were determined in nuclear extracts, and histone
1 (H1) was used as loading control.
(B) NAD+ levels in gastrocnemius muscle of 4-month-old PARP-2+/+ and / male mice (n = 4 and 8, respectively) were determined by HPLC/MS.
(C) SIRT1 mRNA and protein levels were determined in total muscle mRNA or protein extracts.
(D and E) PGC-1a (D) and FOXO1 (E) acetylation lysine levels were examined after immunoprecipitation. Quantifications are shown on top of the respective
images.
(F) Gene expression of the indicated genes in the gastrocnemius muscle of PARP-2+/+ and / mice was evaluated by RT-qPCR.
(G) Quantification of mitochondrial DNA by qPCR.
(H and I) Transmission electron micrographs (H) and SDH staining (I) of representative gastrocnemius muscle sections show increased mitochondrial content
(PARP-2+/+ and / male mice n = 15 and 13, respectively; age of 7 months). Scale bar in (I) = 100 mm.
(J) Endurance treadmill test was performed as described. White bars represent PARP-2+/+ mice, while black bars represent PARP-2/ mice. Values are
expressed as mean ± SEM unless otherwise stated. * indicates statistical difference versus PARP-2+/+ mice at p < 0.05.
Cell Metabolism
PARP-2 Modulates SIRT1 ActivityHigher SIRT1 Activity, Mitochondrial Content,
and Oxidative Profile in PARP-2–/– Tissues
At the molecular level, PARP-2 deletion was not linked to higher
DNA damage in either young or old mice (Figure S2A). In line with
these in vitro data, we could not detect a significant change in
protein PARylation in PARP-2/ mice, as determined by
western blotting (Figure 3A). In contrast to the data from
C2C12 myotubes, PARP-2/ muscles contained more NAD+
(Figure 3B). The data from cultured myotubes suggest that the
increase in NAD+ levels observed in muscle tissue might be
secondary to the leaner phenotype rather than a direct conse-
quence of the reduction in PARP-2 function per se. In line with
the role of PARP-2 as a negative regulator of theSIRT1 promoter,
SIRT1mRNA and protein levels were increased in muscles from
PARP-2/ mice (Figure 3C). The combination of higher NAD+
and higher SIRT1 protein provides an excellent scenario to
increase SIRT1 activity. Confirming this hypothesis, the acetyla-
tion levels of two different SIRT1 substrates, the PPARg coacti-
vator-1a (PGC-1a) (Figure 3D) and the forkhead box O1 (FOXO1)
transcription factor (Figure 3E), were markedly decreased in
muscles from PARP-2/ mice. Importantly, the acetylation
status of SIRT2 and SIRT3 targets, such as tubulin and Ndufa9,Crespectively, was not affected by PARP-2 deletion, indicating
that PARP-2/ deletion is not affecting the activity of the closest
SIRT1 homologs (Figure S2B). PGC-1a and FOXO1 are
transcriptional activators strongly linked to the regulation of
mitochondrial biogenesis and oxidative metabolism. Conse-
quent to their activation through deacetylation, the expression
of transcriptional regulators of oxidative metabolism (PGC-1a),
of biomarkers of oxidative muscle fibers (troponin I [tpnI]),
and of mitochondrial proteins (succinate dehydrogenase [SDH],
uncoupling protein 2 [UCP2]) and lipid oxidation enzymes
(malonyl-CoA decarboxylase [MCD], MCAD) was increased in
gastrocnemius muscle of the PARP-2/ mice (Figure 3F). The
increase in mitochondrial content was further evidenced by the
higher mitochondrial DNA content (Figure 3G) and by the more
prominent mitochondria observed upon transmission electron
microscopy (TEM) analysis of the gastrocnemius muscle
(Figure 3H). The increased mitochondrial biogenesis clearly
promoted a more oxidative phenotype of the PARP-2/
muscles, as reflected by the prominent increase in SDH-positive
oxidative muscle fibers (Figure 3I). As a physiological conse-
quence of this increased oxidative muscle profile, PARP-2/
mice performed much better than their PARP-2+/+ littermatesell Metabolism 13, 450–460, April 6, 2011 ª2011 Elsevier Inc. 453
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Figure 4. PARP-2–/– Mice Display Higher
Mitochondrial Content in Liver
(A) mRNA expression analysis in livers from
PARP-2+/+ and / male (n = 16/13, respectively;
6 months of age) mice fed a chow diet.
(B) Relative liver mitochondrial DNA (mtDNA)
content was estimated by RT-qPCR.
(C) Transmission electron microscopic images of
liver sections demonstrate higher mitochondrial
number in PARP-2/ mice.
(D) Total intrahepatic NAD+ content was measured
by HPLC/MS.
(E) Total liver protein extracts were used to eval-
uate SIRT1 protein levels and immunoprecipitate
PGC-1a to examine PGC-1a acetylation levels.
(F) Liver triglyceride content was estimated after
methanol/chloroform lipid extraction as described.
White bars represent PARP-2+/+ mice, while black
bars represent PARP-2/ mice. Values are ex-
pressed as mean ± SEM unless otherwise stated. *
indicates statistical difference versus PARP-2+/+
mice at p < 0.05.
Cell Metabolism
PARP-2 Modulates SIRT1 Activityon a treadmill endurance test (Figure 3J). As a whole, these
results indicate that PARP-2 deletion promotes mitochondrial
biogenesis in muscle, increasing the oxidative and endurance
profile of the fibers.
We also explored whether PARP-2 deletion could also influ-
ence mitochondrial biogenesis in other highly metabolic tissues,
such as brown adipose tissue (BAT) and liver. In BAT, despite
higher SIRT1 content (Figure S3A), we were unable to detect
changes in the expression of the main metabolic genes
(Figure S3B). Supporting the minor impact of PARP-2 deletion
on BAT function, body temperature dropped similarly in
PARP-2+/+ and PARP-2/ mice upon cold exposure (Fig-
ure S3C). This suggested that BAT is unlikely to contribute signif-
icantly to the differences in EE observed in the PARP-2/mice.
In contrast, PARP-2 deletion had strong effects on the expres-
sion of diverse regulators of mitochondrial metabolism in the
liver, including PGC-1a, PGC-1b, FOXO1, PPARa, estrogen-
related receptor a (ERRa), and Cytochrome C oxidase subunit II
(COXII) (Figure 4A). Consistently, PARP-2/ livers displayed
a higher mitochondrial content, as evidenced by the increase
in mitochondrial DNA levels (Figure 4B) and by the appearance
of more mitochondria upon electron microscopy (Figure 4C).
As in muscle, liver NAD+ content was higher in PARP-2/
mice (Figure 4D), which, together with the higher amounts of
SIRT1 protein, translated into increased SIRT1 activation (Fig-
ure 4E). In line with what was observed in muscle, no changes
in the activity of SIRT2 and SIRT3, the closest SIRT1 homologs,
were detected (Figure S4A). The observation that PARP-2/
livers had a tendency toward a reduced triglyceride content
both upon oil red O staining (Figure S4B) and direct biochemical
measurement (Figure 4F) is consistent with the induction of
oxidative metabolism. Despite the increase in phosphoenolpyr-
uvate carboxykinase (PEPCK) expression in PARP-2/ mice
and the increased capacity of liver for oxidative metabolism,
PARP-2/ mice responded similarly to PARP-2+/+ littermates
upon a pyruvate tolerance test (Figure S4C), probably due to
the similar expression of another rate-limiting enzyme, the
glucose-6-phosphatase (G6Pase) (Figure 4A).454 Cell Metabolism 13, 450–460, April 6, 2011 ª2011 Elsevier Inc.PARP-2–/– Mice Are Protected against Diet-Induced
Obesity and Insulin Resistance
The increased mitochondrial biogenesis and oxidative pheno-
type observed in the skeletal muscle and liver of PARP-2/
mice incited us to test how these mice would respond to
high-fat diet (HFD) feeding. PARP-2/ mice were protected
against weight gain when fed a HFD (Figure 5A), despite
a similar food intake (Figure 5B). This leaner phenotype was
associated with a reduced body fat mass, as evidenced by
EchoMRI analysis (Figure 5C). This reduction in fat content
was clearly more pronounced (20% decrease) in the epidid-
ymal fat depots, which are equivalent to visceral fat in man,
than in the subcutaneous fat pads (Figure 5D). The weight of
the PARP-2/ livers was also markedly reduced (Figure 5D),
consequent to a lower triglyceride accumulation (Figures S5A
and S5B). Accentuating what was observed in chow-fed
mice, PARP-2/ mice on HFD displayed now significantly
higher O2 consumption rates (Figure 5E). The increase in VO2
was not due to increased activity (Figure 5F), indicating that
high-fat-fed PARP-2/ mice have higher basal EE. As ex-
pected, the expression of the transcriptional regulators govern-
ing EE (SIRT1, PGC-1a) was increased in gastrocnemius from
PARP-2/ mice when compared to their PARP-2+/+ littermates
after the HFD (Figure 5G). The expression of several genes
involved in fatty acid uptake and oxidation (muscle carnitine
palmitoyltransferase 1b [mCPT1b], peroxisomal acyl-coenzyme
A oxidase 1 [ACOX1], MCD, MCAD), mitochondrial electron
transport, and oxidative phosphorylation (Ndufa2, Cyt C,
COXIV) followed a pattern similar to these transcriptional
regulators and were maintained at a higher level in the
PARP-2/ muscle (Figure 5G). Consequent to the much leaner
and oxidative phenotype, PARP-2/ mice remained more
insulin sensitive than their wild-type littermates after high-fat
feeding (Figure 5H), and their endurance performance was
markedly better (data not shown). These results clearly indicate
that PARP-2/ mice are protected from body weight gain
and insulin resistance upon high-fat feeding, linked to a better
muscle oxidative phenotype.
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Figure 5. PARP-2–/– Mice Are Protected against Diet-Induced Body Weight Gain and Insulin Resistance
(A) Six-month-old PARP-2+/+ and / male mice (n = 7 and 9, respectively) fed on high-fat diet were weighed weekly.
(B) Food intake was monitored during high-fat feeding.
(C) Body fat mass composition was evaluated through EchoMRI.
(D) The weight of the tissues indicated was determined upon autopsy at the end of the high-fat-feeding period.
(E and F) VO2 (E) and spontaneous activity (F) were determined by indirect calorimetry. Quantification of the mean values during light and dark phases is shown.
(G) mRNA expression levels in gastrocnemius muscles from PARP-2+/+ and / mice after 12 weeks of high-fat diet was determined by RT-qPCR.
(H) Glucose excursion after an intraperitoneal insulin tolerance test. White bars and circles represent PARP-2+/+ mice, while black bars and circles represent
PARP-2/ mice. Values are expressed as mean ± SEM unless otherwise stated. * indicates statistical difference versus PARP-2+/+ mice at p < 0.05.
Cell Metabolism
PARP-2 Modulates SIRT1 ActivityIncreased SIRT1/FOXO1 Activity Renders PARP-2–/–
Mice Glucose Intolerant after High-Fat Feeding
due to Pancreatic Dysfunction
To our surprise, despite their lower body weight and higher
insulin sensitivity, PARP-2/mice were more glucose intolerant
compared to their PARP-2+/+ littermates after high-fat feeding
(Figure 6A) and still displayed fasting hyperglycemia (172.44 ±
20.11 mg/dl for PARP-2+/+ versus 203.34 ± 10.26 mg/dl for
PARP-2/). The fact that PARP-2/mice are also more insulin
sensitive (Figure 5H) suggested that this glucose intolerance
could be related to defects in the insulin release upon a glucose
load. Confirming this hypothesis, the insulin peak after an intra-
peritoneal glucose injection in PARP-2+/+ mice was blunted in
PARP-2/ mice (Figure 6B). Furthermore, fasting blood insulin
levels were lower in PARP-2/ mice (0.87 ± 0.24 mg/l for
PARP-2+/+ versus 0.58 ± 0.16 mg/l for PARP-2/ mice). These
observations led us to examine the pancreas from PARP-2/
mice. HFD increased the pancreatic mass in wild-type mice,
but not in PARP-2-deficient mice (Figure 6C). Histological anal-
ysis of the pancreas of PARP-2+/+ and PARP-2/mice revealed
that islet size was smaller in PARP-2/ mice after high-fat
feeding (Figures 6D and 6E). This reduction in islet size translated
into a robust reduction in pancreatic insulin content (Figure 6F).
When pancreatic gene expression was analyzed in pancreas
from PARP-2+/+ and PARP-2/ mice, it became evident that,
in addition to an increase in some mitochondrial-related genesC(mitochondrial transcription factor A [TFAm], citrate synthase
[CS]), the pancreas of PARP-2/ mice had severe reductions
in the expression of a number of key genes for pancreatic func-
tion (such as glucokinase [GK] and Kir6.2) and proper b cell
growth (pancreatic and duodenal homeobox 1 [pdx1]) (Fig-
ure 6G). Given the reduced insulin content and pdx1 expression,
it was also not surprising that expression of the insulin gene (Ins)
was decreased in the PARP-2/ pancreas (Figure 6G). As in
other tissues, PARP-2 deletion led to higher SIRT1 protein levels
in pancreas (Figure 6H), which translated not only into higher
mitochondrial protein content, as manifested by complex I
(39 kDa subunit) and complex III (47 kDa subunit) levels (Fig-
ure 6H), but also in the constitutive deacetylation of FOXO1 (Fig-
ure 6H). NAD+ levels were similar in pancreas from PARP-2+/+
and / mice (Figure S6A). The deacetylation and activation
of FOXO1 could underpin the pancreatic phenotype of the
PARP-2/ mice, as FOXO1 activity compromises insulin
content and pancreatic growth by acting as a negative regulator
of pdx1 (Kitamura et al., 2002). To further consolidate the hypoth-
esis that higher SIRT1 and/or FOXO1 function is detrimental for
pancreatic function by the downregulation of pdx1, we tested
whether activation of FOXO1 or SIRT1 could decrease pdx1
expression in the MIN6 mouse pancreatic b cell line. Overex-
pression of either FOXO1 or SIRT1 was enough to decrease
pdx1 mRNA and protein levels (Figure 7A). Similarly, resveratrol
treatment, which indirectly activates endogenous SIRT1, leadingell Metabolism 13, 450–460, April 6, 2011 ª2011 Elsevier Inc. 455
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Figure 6. Pancreatic Abnormalities Render PARP-2–/– Mice Glucose Intolerant after High-Fat Feeding
(A) Plasma glucose levels during an intraperitoneal glucose tolerance test (IPGTT) in 9-month-old PARP-2+/+ and / male mice (n = 7 and 9, respectively) fed
a high-fat diet for 12 weeks. The area under the curve of the glucose curves is shown at the right.
(B) Insulin levels during the first hour of the IPGTT in (A).
(C) Comparison of total pancreas weight between PARP-2+/+ and PARP-2/ mice on chow and high-fat diet.
(D) Pancreas from PARP-2+/+ and PARP-2/ mice after high-fat diet were stained for insulin (scale bar = 50 mm).
(E) Mean islet size was quantified.
(F) Total insulin content in pancreas was measured as described.
(G) Gene expression in the pancreas of PARP-2+/+ and PARP-2/ mice was measured by RT-qPCR.
(H) Pancreatic total protein extracts were used to test the abundance of SIRT1, and subunits from the respiratory complexes I and III. FOXO1 was also
immunoprecipitated to determine relative FOXO1 acetylation levels. White bars and circles represent PARP-2+/+ mice, while black bars and circles represent
PARP-2/ mice. Values are expressed as mean ± SEM unless otherwise stated. * indicates statistical difference versus PARP-2+/+ mice at p < 0.05.
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PARP-2 Modulates SIRT1 Activityto FOXO1 deacetylation (Figure 7B), also decreased pdx1
content (Figure 7A). Altogether, these results illustrate that
PARP-2/ mice have impaired pancreatic hyperplasia upon
HFD, due to the lower expression of key genes involved in
pancreatic b cell proliferation and function, such as pdx1, as
a consequence of higher SIRT1 and/or FOXO1 activity.
DISCUSSION
In our present study, we have shown that PARP-2 is a negative
regulator of the SIRT1 promoter and that the reduction or abla-
tion of PARP-2 expression induces SIRT1 expression, protein
content, and activity. As expected from the activation of SIRT1456 Cell Metabolism 13, 450–460, April 6, 2011 ª2011 Elsevier Inc.(Canto´ et al., 2009; Lagouge et al., 2006), PARP-2/ mice
displayed higher whole-body EE and were protected against
HFD-induced obesity. Previous studies on PARP-1, the predom-
inant PARP activity in most tissues, have demonstrated that the
modulation of intracellular NAD+ levels by PARP-1 critically
influences SIRT1 activity (Kolthur-Seetharam et al., 2006; Pillai
et al., 2005; Rajamohan et al., 2009; Bai et al., 2011). Our data
demonstrate that deletion of an alternative PARP activity,
PARP-2, also impacts on SIRT1 activity. Unexpectedly, our
results clearly indicate that, unlike what happens with PARP-1
(Bai et al., 2011), the impact of PARP-2 on SIRT1 activity is not
necessarily based on changes in NAD+ content. This is in line
with previous evidence indicating that PARP-2 is not a major
AC
B Figure 7. Increased SIRT1/FOXO1 Function
Reduces pdx1 Expression
(A and B) MIN6 cells were transfected with either
empty vector (Control), human FLAG-FOXO1, or
human FLAG-SIRT1. Additionally, one empty
vector group was treated with resveratrol (50 mM,
5 hr/day for 2 days). Then, total protein and RNA
extracts were obtained to test pdx1 mRNA and
protein levels (A) and total FOXO1 and acetylated
FOXO1 levels (B), as well as SIRT1 levels.
(C) Scheme illustrating how the activation of PARP
enzymes can downregulate SIRT1 function
through different means. On one hand, PARP-1
activation limits SIRT1 activity by decreasing
NAD+ bioavailability, and on the other, we now
report how PARP-2 acts as a negative regulator of
the SIRT1 promoter. The PARP-1 and PARP-2
knockout mouse models indicate that PARP
inhibition can be useful to promote SIRT1 activity
and enhance mitochondrial content. This strategy
might be exploited therapeutically in the context of
metabolic disease, commonly linked to impaired
mitochondrial content or function. Values are
expressed as mean ± SEM unless otherwise
stated.
Cell Metabolism
PARP-2 Modulates SIRT1 ActivityPARP enzyme in the cell and therefore is not likely to significantly
influence NAD+ homeostasis (Ame´ et al., 1999; Shieh et al.,
1998). Rather, PARP-2 impacts on SIRT1 by directly interacting
with the proximal SIRT1 promoter, where it acts as a potent tran-
scriptional repressor. Accordingly, in all models and tissues
tested, PARP-2 deletion or depletion induces SIRT1 mRNA
expression, protein content, and activity.
PARP-2 can act as a transcriptional regulator (Ye´lamos et al.,
2008). We have previously shown that PARP-2 acts as a positive
regulator of PPARg, leading to triglyceride accumulation (Bai
et al., 2007). In line with this and supported by the present data,
PARP-2 deficiency led to decreased lipid accumulation. Our
current work furthermore expands the potential mechanisms by
which PARP-2 activity might impact on lipid accumulation. First,
the activation of SIRT1 in PARP-2/ mice would provide
a secondway to reduce PPARg activity, as SIRT1 docks the tran-
scriptional corepressors NCoR and SMRT to PPARg-regulated
promoters (Picard et al., 2004). Second, and most importantly,
the increase in EE and fat burning observed in PARP-2/ mice
would also prevent fat accumulation. Reinforcing this second
hypothesis, the reduced size of adipose depots is not associated
with lipid accumulation in other tissues, such as liver (Figures S5A
and S5B), indicating that enhanced fat burning rather than fat
redistribution accounts for the decreased fat mass.Cell Metabolism 13, 450–Our results illustrate how pharmaco-
logical approaches to promote oxidative
metabolism by inhibiting PARP activity
could benefit from targeting specific
PARP enzyme forms. Certainly, PARP-2
deletion recapitulates all the previous
beneficial effects observed with different
strategies aimed to promote SIRT1
activation, i.e., enhanced oxidative
metabolism, endurance phenotype, andprotection against body weight (Feige et al., 2008; Lagouge
et al., 2006). These positive outcomes seen in the absence of
PARP-2 are, however, overshadowed by the deleterious effects
that the absence of PARP-2 has on pancreatic function. Our
results show that, upon high-fat feeding, pancreatic proliferation
and insulin production are blunted in PARP-2/ mice. This
could be a consequence of the impaired expression of pdx1,
a crucial regulator of pancreatic growth and insulin expression
(Kaneto et al., 2008), as well as of other genes that fine-tune
pancreatic function, such as Kir6.2 and glucokinase (MacDonald
et al., 2005). While many reasons could account for such defect,
a likely possibility is that the increased SIRT1 activity in
PARP-2/ pancreas activates FOXO1 (Figure 6H) (Brunet
et al., 2004; Frescas et al., 2005), which is known to downregu-
late pdx1 expression (Kawamori et al., 2006). Interestingly,
decreased FOXO1 activity, through its nuclear exclusion, is
necessary for the compensatory pancreatic proliferation
observed in situations of insulin resistance, as induced by
HFD (Buteau and Accili, 2007). FOXO1 activation also is detri-
mental for the pancreatic proliferative effects of hormones
such as glucagon-like peptide 1 (GLP-1) (Buteau and Accili,
2007). Hence, the constitutive activation of FOXO1 provides
a plausible mechanism to explain the pancreatic phenotype of
the PARP-2/ mice upon HFD. Given that overexpression or460, April 6, 2011 ª2011 Elsevier Inc. 457
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PARP-2 Modulates SIRT1 Activityactivation of SIRT1 or overexpression of FOXO1 in the MIN6
b cell line recapitulates the downregulation of pdx1 in the
PARP-2/ mice, it is surprising that this phenotype was not
observed in other models of SIRT1 activation in the pancreas
(Banks et al., 2008; Moynihan et al., 2005). Unfortunately, the
fact that FOXO1 deacetylation, as a read-out of effective pancre-
atic SIRT1 activation, was not tested in those studies (Banks
et al., 2008; Moynihan et al., 2005) makes it difficult to compare
it with our work. Another possibility would be that, besides
SIRT1-mediated FOXO deacetylation, other PARP-2-specific
functions might contribute to the pancreatic alterations in the
PARP-2/ mice. For example, PARPs can modulate the enzy-
matic activities of a number of proteins through direct interaction
or by poly(ADP-ribosyl)ation (Ye´lamos et al., 2008). In this sense,
PARP-1 is known to directly interact with, poly(ADP-ribosyl)ate,
and inhibit FOXO (Sakamaki et al., 2009), but we could not
demonstrate an interaction between PARP-2 and FOXO in the
pancreas (Figure S6B). Notably, we also could not find evidence
for a direct interaction between PARP-2 and SIRT1 (Figure S1B)
or poly(ADP-ribosyl)ation of SIRT1 (Bai et al., 2011). Further-
more, PARP-2 deletion affects blood adipokine levels (Bai
et al., 2007), whichmight also impact pancreatic function. Unrav-
eling the additional mechanisms by which PARP-2 influences
pancreatic function warrants future investigation. Importantly, it
must be noted that this pancreatic phenotype is specific for
the PARP-2/ mice, as PARP-1/ mice, while sharing many
common characteristics with the PARP-2 mutants, do not
develop glucose intolerance after high-fat feeding (Bai et al.,
2011), and islet size and insulin content are similar between
wild-type and PARP-1/ littermates upon high-fat feeding
(Figures S6C and S6D), indicating that the pancreatic phenotype
is specific to PARP-2 deletion.
In conclusion, our results complement the picture by which
PARP activation is detrimental for mitochondrial function by
decreasing SIRT1 activity (Figure 7C). On the one hand, we
recently reported that the activation of PARP-1 depletes intracel-
lular NAD+, which limits SIRT1 activity (Bai et al., 2011). On the
other hand, we describe here how PARP-2 acts as a negative
regulator of SIRT1 expression. In combination, these results
prompt the speculation that PARP inhibitors could be used not
only for cancer, but also in the context of metabolic disease to
enhance mitochondrial content.
EXPERIMENTAL PROCEDURES
Materials
All chemicals were from Sigma-Aldrich (St. Louis) unless stated otherwise.
Animal Studies
All animal experiments were carried out according to local, national, and EU
ethical guidelines. Homozygous PARP-2/ and littermate PARP-2+/+ mice
(Me´nissier de Murcia et al., 2003) and PARP-1/ and PARP-1+/+ mice (de
Murcia et al., 1997) on a mixed C57BL/6J / SV129 background (87.5%/
12.5%) background from heterozygous crossings were used. Mice were
housed separately, had ad libitum access to water and food, and were kept
under a 12/12 hr dark/light cycle. Mice were selected for the study at the
age of 4 weeks and were kept on chow diet (10 kcal% of fat, Safe, Augy,
France). For a part of the animals, food was changed by a HFD (60 kcal% of
fat, Research Diets, New Brunswick, NJ) at the age of 16 weeks. Each week
on the same day, mice were weighed and food consumption was measured.
O2 consumption, CO2 production, and actimetry were measured by CLAMS458 Cell Metabolism 13, 450–460, April 6, 2011 ª2011 Elsevier Inc.of Columbus Instruments; total body fat was measured by EchoMRI as
described (Lagouge et al., 2006; Watanabe et al., 2006). Endurance test was
performed as described in Canto´ et al. (2009). Intraperitoneal glucose and
insulin tolerance tests (IPGTT and IPITT, respectively) were performed as
previously described (Feige et al., 2008). The animals were killed by CO2
asphyxiation after 6 hr of fasting, and tissues were collected. Total body fat
content was then examined at autopsy by weighing the subcutaneous,
gonadal, mesenterial, retroperitoneal, and BAT-associated fat depots. Liver
triglyceride was determined after Folch extraction using a commercial triglyc-
eride kit (Roche). Pancreas and plasma insulin content was determined from
acidic extracts using a commercial ELISA kit (Mercodia) (Champy et al., 2004).
Histology and Microscopy
Hematoxylin-eosin (HE), oil red O, and SDH stainings were performed on 7 mm
tissue sections as described (Lagouge et al., 2006; Picard et al., 2002). Immu-
nohistochemistry was performed on 7 mm frozen tissue sections using anti-
insulin antibody (Dako). Aspecific binding of the secondary antibody was
controlled on sections where the primary antibody was omitted. Islet size
was determined on insulin-stained sections. TUNEL assay was performed
using a commercial kit (Millipore). TEM was performed on glutaraldehyde-
fixed, ismium tetroxide-stained ultrafine sections (Watanabe et al., 2006).
Cell Culture
HEK293T cells were cultured as described in Bai et al. (2007). TheMIN6mouse
pancreatic b cell line was grown in DMEM 4.5 g/l glucose with 15% inactivated
FBS, 1% penicillin/streptomycin, 2 mM glutamine, and 50 mM 2-mercaptoe-
thanol. C2C12 cells were cultured and differentiated as described in Canto´
et al. (2009). Lentiviral short hairpin (shRNA) and control scramble constructs
against PARP-2 were from Sigma-Aldrich (MISSION Custom Vector) incorpo-
rating the interfering sequence described in Bai et al. (2007). C2C12 cells were
transduced with 20 moi of virus, and transduced clones were selected with
2.5 mg/ml puromycin. Puromycin selection was maintained during subsequent
routine cell culture.
Constructs, Reporter Assays, and Chromatin Immunoprecipitation
SIRT1 promoter constructs were described in Nemoto et al. (2004). pSuper-
siPARP2, pSuper-scrPARP2, and pBabe-PARP2 were described in Bai et al.
(2007). Adenovirus for SIRT1 knockdown is reported in Rodgers et al. (2005).
Reporter assays and ChIPs were performed as in Bai et al. (2007). Primers
for ChIP are summarized in Table S3.
mRNA Preparation, Reverse Transcription, and qPCR
Messenger RNA preparation, cDNA synthesis, and RT-qPCR were performed
as described in Bai et al. (2007). Expression was normalized to the expression
of cyclophilin. Mitochondrial DNA was determined in qPCR reactions as
described in Lagouge et al. (2006). Primers are summarized in Tables S1
and S2.
NAD+ Determination
NAD+ was determined by either a general alcohol-dehydrogenase-coupled
colorimetric reaction (Canto´ et al., 2009) or, where indicated, by mass spec-
trometry, as described (Sauve et al., 2005).
Protein Extraction and Western Blotting
Protein extracts were prepared as described in Canto´ et al. (2009); nuclear
extraction was prepared as described (Edelman et al., 1965). Extracts were
subjected to western blotting as in Bai et al. (2007) and Canto´ et al. (2009).
Blots were probed with the following primary antibodies: SIRT1 (Millipore),
actin (Sigma), PARP-2 (rabbit polyclonal antibody raised against full-length
mouse PARP-2), and H1 (kindly provided by S. Muller, IBMC, Strasbourg).
Determination of PGC-1a Acetylation Status
PGC-1a and FOXO1 acetylation was analyzed by immunoprecipitation as
described in Canto´ et al. (2009).
Statistical Analysis
For the statistical analysis of the animal studies (body weight gain, food
consumption), the data were checked for normal distribution. To determine
Cell Metabolism
PARP-2 Modulates SIRT1 Activitysignificance, Student’s t test was applied, and p < 0.05 was considered
significant. Error bars represent SEM unless stated otherwise.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Supplemental References, six figures, and two tables and can be found with
this article online at doi:10.1016/j.cmet.2011.03.013.
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